Brightgene Bio-medical Technology Co (SHSE:688166) Long-Term Debt : ¥1,613 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Brightgene Bio-medical Technology Co Long-Term Debt?

Brightgene Bio-medical Technology Co's Long-Term Debt for the quarter that ended in Mar. 2025 was ¥1,613 Mil.

Brightgene Bio-medical Technology Co's quarterly Long-Term Debt increased from Sep. 2024 (¥1,553 Mil) to Dec. 2024 (¥1,565 Mil) and increased from Dec. 2024 (¥1,565 Mil) to Mar. 2025 (¥1,613 Mil).

Brightgene Bio-medical Technology Co's annual Long-Term Debt increased from Dec. 2022 (¥1,576 Mil) to Dec. 2023 (¥1,615 Mil) but then declined from Dec. 2023 (¥1,615 Mil) to Dec. 2024 (¥1,565 Mil).

Brightgene Bio-medical Technology Co Long-Term Debt Historical Data

The historical data trend for Brightgene Bio-medical Technology Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brightgene Bio-medical Technology Co Long-Term Debt Chart

Brightgene Bio-medical Technology Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Debt

Get a 7-Day Free Trial

77.52

618.69

1,576.05

1,614.92

1,565.28

Brightgene Bio-medical Technology Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Long-Term Debt	Get a 7-Day Free Trial															1,540.12	1,709.64	1,552.61	1,565.28	1,613.28

Brightgene Bio-medical Technology Co (SHSE:688166) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Brightgene Bio-medical Technology Co Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Brightgene Bio-medical Technology Co's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Brightgene Bio-medical Technology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brightgene Bio-medical Technology Co Ltd (SHSE:688166) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Xinghu Street, Industrial Park, Building C25-C28, Bio-Nano Park, No. 218, Suzhou, CHN, 215123

Website

http://www.bright-gene.com

Brightgene Bio-medical Technology Co Ltd is a pharmaceutical company engaged in research, development and production of new drugs and high-end generic drugs. The company develops macrolides, peptides, polysaccharides, heterocycles, azoles, azines, phenyl ethers, tetracyclines, and production of non-pharmaceutical macrolides, peptides, polysaccharides, heterocycles, azoles, azines, benzene Ethers, tetracyclines.

Brightgene Bio-medical Technology Co Headlines

No Headlines